Review

Intraductal delivery of nanocarriers for ductal carcinoma in situ treatment: a strategy to enhance localized delivery

*Author for correspondence:

Department of Pharmaceutical Technology, School of Pharmacy, International Medical University, Kuala Lumpur, 57000, Malaysia

Department of Pharmaceutical Sciences, Central University of Haryana, Mahendergarh, 123031, India

Search for more papers by this author

Pung Xiau Wen

School of Pharmacy, International Medical University, Kuala Lumpur, 57000, Malaysia

Search for more papers by this author

Giam Mun Ning

School of Pharmacy, International Medical University, Kuala Lumpur, 57000, Malaysia

Search for more papers by this author

Gan Jia Xing

School of Pharmacy, International Medical University, Kuala Lumpur, 57000, Malaysia

Search for more papers by this author

Liu Man Wei

School of Pharmacy, International Medical University, Kuala Lumpur, 57000, Malaysia

Search for more papers by this author

Dinesh Kumar

Department of Pharmaceutical Sciences, Central University of Haryana, Mahendergarh, 123031, India

Search for more papers by this author

Jayashree Mayuren

Department of Pharmaceutical Technology, School of Pharmacy, International Medical University, Kuala Lumpur, 57000, Malaysia

Search for more papers by this author

Mayuren Candasamy

**Author for correspondence:

E-mail Address: MayurenCandasamy@imu.edu.my

Department of Life Sciences, School of Pharmacy, International Medical University, Kuala Lumpur, 57000, Malaysia

Search for more papers by this author

Bapi Gorain

Department of Pharmaceutical Sciences & Technology, Birla Institute of Technology, Mesra, Ranchi, 835215, India

Search for more papers by this author

Neha Jain

Department of Pharmaceutics, Amity Institute of Pharmacy, Amity University, Noida, India

Search for more papers by this author

Gaurav Gupta

https://orcid.org/0000-0001-7941-0229

School of Pharmacy, Suresh Gyan Vihar University, Jagatpura, Jaipur, 302017, India

Department of Pharmacology, Saveetha Dental College, Saveetha Institute of Medical & Technical Sciences, Saveetha University, Chennai, 602105, India

Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, 248007, India

Search for more papers by this author

Kamal Dua

https://orcid.org/0000-0002-7507-1159

Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, NSW 2007, Australia

Faculty of Health, Australian Research Centre in Complementary & Integrative Medicine, University of Technology Sydney, Ultimo, NSW 2007, Australia

Search for more papers by this author

Published Online:25 Jan 2023https://doi.org/10.2217/nnm-2022-0234

View article

Abstract

Ductal carcinoma in situ describes the most commonly occurring, noninvasive malignant breast disease, which could be the leading factor in invasive breast cancer. Despite remarkable advancements in treatment options, poor specificity, low bioavailability and dose-induced toxicity of chemotherapy are the main constraint. A unique characteristic of nanocarriers may overcome these problems. Moreover, the intraductal route of administration serves as an alternative approach. The direct nanodrug delivery into mammary ducts results in the accumulation of anticancer agents at targeted tissue for a prolonged period with high permeability, significantly decreasing the tumor size and improving the survival rate. This review focuses mainly on the intraductal delivery of nanocarriers in treating ductal carcinoma in situ, together with potential clinical translational research.

Plain language summary

Ductal carcinoma in situ (DCIS) describes the most commonly occurring, noninvasive malignant breast disease, in which it could be the leading factor to invasive breast cancer. Mammography screening is often the diagnosis method in DCIS. The conventional treatment of DCIS includes breast-conserving surgery, medical treatment, chemotherapy and hormonal therapy. Various approaches are now actively investigated to overcome a number of drawbacks presented in conventional drug-delivery systems. Incorporation of nanocarriers in the drug-delivery system has portrayed certain benefits over the conventional therapy in DCIS where it promotes targeting in tumor cells, in which provision of the maximum therapeutic effects with minimal adverse effects are eventually achieved. With direct intraductal delivery, the drug accumulates at the site of action. Discovery on the intraductal route of administration has also been greatly implemented in managing other diseases.

Tweetable abstract

Intraductal delivery of chemotherapeutics for the treatment of DCIS avoids systemic toxicity and greater therapeutic response.

Keywords:

Papers of special note have been highlighted as: • of interest

References

1. Do Nascimento RG, Otoni KM. Histological and molecular classification of breast cancer: what do we know? Mastology. 30, 1–5 (2020).
Google Scholar
2. Giannakeas V, Sopik V, Narod SA. Association of a diagnosis of ductal carcinoma in situ with death from breast cancer. JAMA Netw. Open. 3(9), e2017124–e2017124 (2020).
MedlineGoogle Scholar
3. World Health Organization. Breast cancer (2021). www.who.int/news-room/fact-sheets/detail/breast-cancer
Google Scholar
4. American Cancer Society. Ductal carcinoma in situ (DCIS) (2021). www.cancer.org/cancer/breast-cancer/about/types-of-breast-cancer/dcis.html
Google Scholar
5. Łukasiewicz S, Czeczelewski M, Forma A et al. Breast cancer – epidemiology, risk factors, classification, prognostic markers, and current treatment strategies – an updated review. Cancers (Basel) 13(17), 4287 (2021).
Medline CASGoogle Scholar
6. Zuo Q, Band S, Kesavadas M, Madak Erdogan Z. Obesity and postmenopausal hormone receptor-positive breast cancer: epidemiology and mechanisms. Endocrinology 162(12), (2021).
MedlineGoogle Scholar
7. Howard FM, Olopade OI. Epidemiology of triple-negative breast cancer: a review. Cancer J. 27(1), (2021).
MedlineGoogle Scholar
8. International Agency for Research on Cancer, World Health Organization. Global Cancer Observatory 2018 (2020). https://www.breastcancer.org/facts-statistics
Google Scholar
9. Canadian Cancer Statistics Advisory Committee, Canadian Cancer Society. Canadian Cancer Statistics 2021. Statistics Canada and the Public Health Agency of Canada. (2021). https://cancer.ca/en/research/cancer-statistics
Google Scholar
10. Breastcancer.org U.S. Breast Cancer Statistics. Breastcancer.org (2021). www.breastcancer.org/symptoms/understand_bc/statistics
Google Scholar
11. Yang M, Xu Z, Zhang QZ et al. A breast one-patient panel of heterogeneous genomes reveals genetic alterations driving DCIS into invasive lesions. Future Oncol. 15(14), (2019).
Google Scholar
12. Tsang JY, Tse GM. Narrowing down the focus: what are the main predictive markers for ductal carcinoma in situ? Breast Cancer Manag. 3(3), (2014).
Google Scholar
13. Coleman WB. Breast ductal carcinoma in situ: precursor to invasive breast cancer. Am. J. Pathol. 189(5), 942–945 (2019).
MedlineGoogle Scholar
14. Benson JR. Diagnosis and local management of breast cancer: part II. Future Oncol. 7(8), 959–61 (2011).
Google Scholar
15. Castro NP, Osório CA, Torres C et al. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma. Breast Cancer Res. 10(5), (2008).
MedlineGoogle Scholar
16. Tomlinson-Hansen S, Khan M, Cassaro S. Breast ductal carcinoma in situ. StatPearls Publishing, FL, USA (2022).
Google Scholar
17. van Seijen M, Lips EH, Thompson AM et al. Ductal carcinoma in situ: to treat or not to treat, that is the question. Br. J. Cancer 121(4), 285–292 (2019).
MedlineGoogle Scholar
18. Heywang-Köbrunner SH, Hacker A, Sedlacek S. Advantages and disadvantages of mammography screening. Breast Care 6(3), 199 (2011). www.ncbi.nlm.nih.gov/pmc/articles/PMC3132967/
MedlineGoogle Scholar
19. Trecate G, Sinues PML, Orlandi R. Noninvasive strategies for breast cancer early detection. Future Oncol. 12(11), (2016).
Google Scholar
20. Voogd AC. The impact of mammography screening on breast cancer incidence. J. Comp. Eff. Res. 2(2), 113–116 (2013).
MedlineGoogle Scholar
21. Puliti D, Paci E. The other side of technology: risk of overdiagnosis of breast cancer with mammography screening. Future Oncol. 5(4), (2009).
Google Scholar
22. Riedel F, Hennigs A, Hug S et al. Is mastectomy oncologically safer than breast-conserving treatment in early breast cancer? Breast Care (Basel) 12(6), 385–390 (2017).
MedlineGoogle Scholar
23. Poortmans P. Optimal approach in early breast cancer: radiation therapy. Eur. J. Cancer Suppl. 11(2), 27–36 (2013).
Google Scholar
24. Miligy IM, Toss MS, Khout H et al. Surgical management of ductal carcinoma in situ of the breast: a large retrospective study from a single institution. Breast J. 25(6), 1143–1153 (2019).
MedlineGoogle Scholar
25. Pawloski KR, Tadros AB, Sevilimedu V et al. Patterns of invasive recurrence among patients originally treated for ductal carcinoma in situ by breast-conserving surgery versus mastectomy. Breast Cancer Res. Treat. 186(3), 617–624 (2021).
MedlineGoogle Scholar
26. Gupta A, Jhawar SR, Sayan M et al. Cost-effectiveness of adjuvant treatment for ductal carcinoma in situ. J. Clin. Oncol. 39(21), 2386–2396 (2021).
Medline CASGoogle Scholar
27. Solin LJ, Gray R, Hughes LL et al. Surgical excision without radiation for ductal carcinoma in situ of the breast: 12-year results from the ECOG-ACRIN E5194 study. J. Clin. Oncol. 33(33), 3938–3944 (2015).
MedlineGoogle Scholar
28. Gupta P, Neupane YR, Parvez S, Kohli K. Recent advances in targeted nanotherapeutic approaches for breast cancer management. Nanomedicine 16(29), (2021).
Google Scholar
29. Pucci P. Combination therapy and noncoding RNAs: a new era of cancer personalized medicine. Epigenomics 14(3), 117–120 (2022).
CASGoogle Scholar
30. Dubey SK, Kali M, Hejmady S et al. Recent advances of dendrimers as multifunctional nano-carriers to combat breast cancer. Eur. J. Pharm. Sci. 164, 105890 (2021).
Medline CASGoogle Scholar
31. Kaur IP, Singh J, Goel S et al. Nanotechnology based docetaxel: upcoming avenue for breast cancer management. Unraveling the Complexities of Metastasis. Academic Press, CA, USA, 105–124 (2022).
Google Scholar
32. Jahan S, Karim ME, Chowdhury EH. Nanoparticles targeting receptors on breast cancer for efficient delivery of chemotherapeutics. Biomedicines 9(2), 1–30 (2021).
Google Scholar
33. Maheshwari R, Tekade M, Gondaliya P et al. Recent advances in exosome-based nanovehicles as RNA interference therapeutic carriers. Nanomedicine 12(21), 2653–2675 (2017).
CASGoogle Scholar
34. Cao XH, Liang MX, Wu Y et al. Extracellular vesicles as drug vectors for precise cancer treatment. Nanomedicine 16(17), 1519–1537 (2021).
CASGoogle Scholar
35. Sun S-S, Zhang B, Zhao H-M, Cao X-C. Association between mammographic features and clinicopathological characteristics in invasive ductal carcinoma of breast cancer. Mol. Clin. Oncol. 2(4), 623–629 (2014).
MedlineGoogle Scholar
36. Choi SH, Choi JS, Han BK et al. Long-term surveillance of ductal carcinoma in situ detected with screening mammography versus US: factors associated with second breast cancer. Radiology 292(1), 37–48 (2019).
MedlineGoogle Scholar
37. Yip C-H. Challenges in the early detection of breast cancer in resource-poor settings. Breast Cancer Manag. 5(4), 161–169 (2016).
CASGoogle Scholar
38. Mehmood M, Ayub E, Ahmad F et al. Machine learning enabled early detection of breast cancer by structural analysis of mammograms. Comput. Mater. Continua 67(1), 641–657 (2021).
Google Scholar
39. Farante G, Toesca A, Magnoni F et al. Advances and controversies in management of breast ductal carcinoma in situ (DCIS). Eur. J. Surg. Oncol. 48(4), 736–741 (2021).
MedlineGoogle Scholar
40. van Seijen M, Lips EH, Thompson AM et al. Ductal carcinoma in situ: to treat or not to treat, that is the question. Br. J. Cancer 121(4), 285–292 (2019).
MedlineGoogle Scholar
41. Feng Y, Spezia M, Huang S et al. Breast cancer development and progression: risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis. 5(2), 77 (2018).
Medline CASGoogle Scholar
42. Tjalma W. Is anti-hormonal treatment in DCIS of the breast a need? Facts Views Vis. Obstetr. Gynaecol. 8(3), 179–181 (2016).
MedlineGoogle Scholar
43. Zhang J, Lu CY, Chen HM, Wu SY. Neoadjuvant chemotherapy or endocrine therapy for invasive ductal carcinoma of the breast with high hormone receptor positivity and human epidermal growth factor receptor 2 negativity. JAMA Netw. Open. 4(3), e211785–e211785 (2021).
MedlineGoogle Scholar
44. Reimers LL, Sivasubramanian PS, Hershman D et al. Breast cancer chemoprevention among high-risk women and those with ductal carcinoma in situ. Breast J. 21(4), 377–386 (2015).
Medline CASGoogle Scholar
45. Nounou MI, ElAmrawy F, Ahmed N et al. Breast cancer: conventional diagnosis and treatment modalities and recent patents and technologies. Breast Cancer (Auckl) 9(Suppl. 2) 17–34 (2015).
Medline CASGoogle Scholar
46. Al-Zubaydi F, Gao D, Kakkar D et al. Breast intraductal nanoformulations for treating ductal carcinoma in situ I: exploring metal–ion complexation to slow ciclopirox release, enhance mammary persistence and efficacy. J. Control. Rel. 323, 71–82 (2020). • Investigates the chemotherapeutic effects of intraductal administration of ciclopirox loaded nanocarriers.
Medline CASGoogle Scholar
47. Sharma A, Jain N, Sareen R. Nanocarriers for diagnosis and targeting of breast cancer. Biomed. Res. Int. 2013 (2013).
Google Scholar
48. Killelea BK, Dixon JM. Ductal carcinoma in situ: a ticking time bomb. Breast Cancer Manag. 2(2), 85–88 (2013).
CASGoogle Scholar
49. Lee O, Khan SA. Novel routes for administering chemoprevention: local transdermal therapy to the breasts. Semin. Oncol. 43(1), 107–115 (2016).
Medline CASGoogle Scholar
50. Mahoney ME, Gordon EJ, Rao JY et al. Intraductal therapy of ductal carcinoma in situ: a presurgery study. Clin. Breast Cancer 13(4), 280 (2013).
MedlineGoogle Scholar
51. Neupane R, Boddu SHS, Abou-Dahech MS et al. Transdermal delivery of chemotherapeutics: strategies, requirements, and opportunities. Pharmaceutics 13(7), 960 (2021).
Medline CASGoogle Scholar
52. Singh SK, Singh S, Wlillard J, Singh R. Drug delivery approaches for breast cancer. Int. J. Nanomed. 12, 6205–6218 (2017).
Medline CASGoogle Scholar
53. King BL, Love SM. The intraductal approach to the breast: raison d'être. Breast Cancer Res. 8(2), 1–10 (2006).
Google Scholar
54. Stearns V, Mori T, Jacobs LK et al. Breast cancer: preclinical and clinical evaluation of intraductally administered agents in early breast cancer. Sci. Transl. Med. 3(106), 106ra108–106ra108 (2011).
MedlineGoogle Scholar
55. Krause S, Brock A, Ingber DE. Intraductal injection for localized drug delivery to the mouse mammary gland. J. Vis. Exp. (80), 50692 (2013).
MedlineGoogle Scholar
56. Zhang B, Love SM, Chen G et al. The safety parameters of the study on intraductal cytotoxic agent delivery to the breast before mastectomy. Chin. J. Cancer 26(5), 579 (2014).
Google Scholar
57. Krishnamurthy S, Ke X, Yang YY. Delivery of therapeutics using nanocarriers for targeting cancer cells and cancer stem cells. Nanomedicine 10(1), 143–160 (2015).
CASGoogle Scholar
58. Din FU, Aman W, Ullah I et al. Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors. Int. J. Nanomed. 12, 7291–7309 (2017).
MedlineGoogle Scholar
59. Yan W, Leung SSY, To KKW. Updates on the use of liposomes for active tumor targeting in cancer therapy. Nanomedicine 15(3), 303–318 (2019).
Google Scholar
60. Cohen SM, Mukerji R, Cai S et al. Subcutaneous delivery of nanoconjugated doxorubicin and cisplatin for locally advanced breast cancer demonstrates improved efficacy and decreased toxicity at lower doses than standard systemic combination therapy in vivo. Am. J. Surg. 202(6), 646–653 (2011).
Medline CASGoogle Scholar
61. Yao Y, Zhou Y, Liu L et al. Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance. Front. Mol. Biosci. 7, 193 (2020).
Medline CASGoogle Scholar
62. Gigliobianco MR, Casadidio C, Censi R, di Martino P. Nanocrystals of poorly soluble drugs: drug bioavailability and physicochemical stability. Pharmaceutics 10(3), 134 (2018).
Medline CASGoogle Scholar
63. Jin KT, Lu ZB, Chen JY et al. Recent trends in nanocarrier-based targeted chemotherapy: selective delivery of anticancer drugs for effective lung, colon, cervical, and breast cancer treatment. J. Nanomater. (2020). www.hindawi.com/journals/jnm/2020/9184284/
Google Scholar
64. Yoo J, Park C, Yi G et al. Active targeting strategies using biological ligands for nanoparticle drug delivery systems. Cancers 11(5), 640 (2019). www.mdpi.com/journal/cancers
Medline CASGoogle Scholar
65. Omurtag Ozgen PS, Atasoy S, Zengin Kurt B et al. Glycopolymer decorated multiwalled carbon nanotubes for dual targeted breast cancer therapy. J. Mater. Chem. B 8(15), 3123–3137 (2020).
MedlineGoogle Scholar
66. Thakur N, Thakur S, Chatterjee S et al. Nanoparticles as smart carriers for enhanced cancer immunotherapy. Front. Chem. 8, 1217 (2020).
Google Scholar
67. Li Y, Zhang X, Liu X et al. Designing and engineering of nanocarriers for bioapplication in cancer immunotherapy. ACS Appl. Bio. Mater. 3(12), 8321–8337 (2020).
Medline CASGoogle Scholar
68. Waheed S, Li Z, Zhang F et al. Engineering nano-drug biointerface to overcome biological barriers toward precision drug delivery. J. Nanobiotechnol. 20(1), 395 (2022). • Investigates the effect of formulation type and particle size on the retention of formulation at the breast duct.
MedlineGoogle Scholar
69. Manzoor AA, Lindner LH, Landon CD et al. Overcoming limitations in nanoparticle drug delivery: triggered, intravascular release to improve drug penetration into tumors. Cancer Res. 72(21), 5566–5575 (2012). • Focuses on a phase I clinical trial to evaluate the feasibility and safety of chemo drugs via the intraductal route in women with invasive cancer.
Medline CASGoogle Scholar
70. Patra JK, Das G, Fraceto LF et al. Nano based drug delivery systems: recent developments and future prospects. J. Nanobiotechnol. 16(1), 1–33 (2018). • Investigates the benefits of intraductal delivery compared to intravenous delivery of paclitaxel in tumor-bearing Sprague–Dawley mice.
MedlineGoogle Scholar
71. Gu Z, Al-Zubaydi F, Adler D et al. Evaluation of intraductal delivery of poly(ethylene glycol)-doxorubicin conjugate nanocarriers for the treatment of ductal carcinoma in situ (DCIS)-like lesions in rats. J. Interdiscip. Nanomed. 3(3), 146 (2018). • Focuses on the effectiveness of intraductal administration of 4-hydroxytamoxifen (4-OHT) and pegylated liposomal doxorubicin in the prevention and treatment of rat mammary tumors induced by N-methyl-N-nitrosourea.
Medline CASGoogle Scholar
72. Migotto A, Carvalho VFM, Salata GC et al. Multifunctional nanoemulsions for intraductal delivery as a new platform for local treatment of breast cancer. Drug Deliv. 25(1), 654–667 (2018). • Focuses on the delivery of a natural product (curcumin) via an intraductal route and its effectiveness in tumor-bearing mice.
Medline CASGoogle Scholar
73. Mojeiko G, Passos JS, Apolinario AC, Lopes LB. Topical transdermal chemoprevention of breast cancer: where will nanomedical approaches deliver us? Nanomedicine 16(19), 1713–1731 (2021).
CASGoogle Scholar
74. Husain S, Yu M, Khalid A. Optimizing a novel intraductal delivery of calcineurin inhibitors as a radiocontrast infusion formulation to prevent post-ERCP pancreatitis. STANFORD UNIV CA (2021). https://apps.dtic.mil/sti/citations/AD1118329
Google Scholar
75. Schwalje AT, Hoffman HT. Intraductal salivary gland infusion with botulinum toxin. Laryngoscope Investig. Otolaryngol. 4(5), 520–525 (2019).
MedlineGoogle Scholar
76. Salata GC, Lopes LB. Phosphatidylcholine-based nanoemulsions for paclitaxel and a P-glycoprotein inhibitor delivery and breast cancer intraductal treatment. Pharmaceuticals 15(9), 1110 (2022). www.mdpi.com/1424-8247/15/9/1110
Medline CASGoogle Scholar
77. Juliano RL. The role of drug delivery systems in cancer chemotherapy. Prog. Clin. Biol. Res. 9, 21–32 (1976).
Medline CASGoogle Scholar
78. Joseph MK, Islam M, Reineke J et al. Intraductal drug delivery to the breast: effect of particle size and formulation on breast duct and lymph node retention. Mol. Pharm. 17(2), 441–452 (2020).
Medline CASGoogle Scholar
79. Love SM, Zhang W, Gordon EJ et al. A feasibility study of the intraductal administration of chemotherapy. Cancer Prev. Res. 6(1), 51–58 (2013).
Medline CASGoogle Scholar
80. Okugawa H, Yamamoto D, Uemura Y et al. Effect of perductal paclitaxel exposure on the development of MNU-induced mammary carcinoma in female S-D rats. Breast Cancer Res. Treat. 91(1), 29–34 (2005).
Medline CASGoogle Scholar
81. Murata S, Kominsky SL, Vali M et al. Ductal access for prevention and therapy of mammary tumors. Cancer Res. 66(2), 638–645 (2006).
Medline CASGoogle Scholar
82. Chun YS, Bisht S, Chenna V et al. Intraductal administration of a polymeric nanoparticle formulation of curcumin (NanoCurc) significantly attenuates incidence of mammary tumors in a rodent chemical carcinogenesis model: implications for breast cancer chemoprevention in at-risk populations. Carcinogenesis 33(11), 2242–2249 (2012).
Medline CASGoogle Scholar
83. Najahi-Missaoui W, Arnold RD, Cummings BS. Safe nanoparticles: are we there yet? Int. J. Mol. Sci. 22(1), 385 (2021). www.mdpi.com/1422-0067/22/1/385
CASGoogle Scholar
84. Yousef MI, Mutar TF, Kamel MAEN. Hepato-renal toxicity of oral sub-chronic exposure to aluminum oxide and/or zinc oxide nanoparticles in rats. Toxicol. Rep. 6, 336–346 (2019).
Medline CASGoogle Scholar
85. Youngwirth LM, Boughey JC, Hwang ES. Surgery versus monitoring and endocrine therapy for low-risk DCIS: the COMET Trial. Bull. Am. Coll. Surg. 102(1), 62–63 (2017).
MedlineGoogle Scholar
86. Elshof LE, Tryfonidis K, Slaets L et al. Feasibility of a prospective, randomized, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ – the LORD study. Eur. J. Cancer 51(12), 1497–1510 (2015).
MedlineGoogle Scholar
87. Maxwell AJ, Hilton B, Clements K et al. Unresected screen-detected ductal carcinoma in situ: outcomes of 311 women in the Forget-Me-Not 2 study. Breast 61, 145–155 (2022).
MedlineGoogle Scholar
88. Shelley Hwang E, Hyslop T, Hendrix LH et al. Phase II single-arm study of preoperative letrozole for estrogen receptor-positive postmenopausal ductal carcinoma in situ: CALGB 40903 (Alliance). J. Clin. Oncol. 38(12), 1284 (2020).
MedlineGoogle Scholar
89. Joseph MK, Islam M, Reineke J et al. Intraductal drug delivery to the breast: effect of particle size and formulation on breast duct and lymph node retention. Mol. Pharm. 17(2), 441–452 (2020).
Medline CASGoogle Scholar
90. Wang Y, Santos A, Evdokiou A, Losic D. An overview of nanotoxicity and nanomedicine research: principles, progress and implications for cancer therapy. J. Mater. Chem. B3(36), 7153–7172 (2015).
Google Scholar
91. Hossen S, Hossain MK, Basher MK et al. Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: a review. J. Adv. Res. 15, 1–18 (2019).
Medline CASGoogle Scholar
92. Mühlebach S. Regulatory challenges of nanomedicines and their follow-on versions: a generic or similar approach? Adv. Drug Deliv. Rev. 131, 122–131 (2018).
Medline CASGoogle Scholar

Vol. 17, No. 24

Supplemental Materials

Metrics

Downloaded 68 times

History

Received 7 September 2022

Accepted 28 November 2022

Published online 25 January 2023

Published in print October 2022

Information

Keywords

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at: www.futuremedicine.com/doi/suppl/10.2217/nnm-2022-0234

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

PDF download